Pharsight

Drugs that contain Entrectinib

1. Rozlytrek patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9029356 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(4 years from now)

US8299057 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Mar, 2029

(5 years from now)

US9085565 GENENTECH INC Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2033

(9 years from now)

US10738037 GENENTECH INC Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2037

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8673893 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(4 years from now)

US9255087 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(4 years from now)

US9085558 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(4 years from now)

US9616059 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(4 years from now)

US9649306 GENENTECH INC Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2033

(9 years from now)

US10231965 GENENTECH INC Molecules for administration to ROS1 mutant cancer cells
Feb, 2035

(10 years from now)

US10561651 GENENTECH INC Methods for treating neuroblastoma
Feb, 2035

(10 years from now)

US11091469 GENENTECH INC Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2037

(13 years from now)

US11253515 GENENTECH INC Pharmaceutical compositions and dosage forms
Jul, 2038

(14 years from now)

US10398693 GENENTECH INC Pharmaceutical compositions and dosage forms
Jul, 2038

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 20, 2030
New Chemical Entity Exclusivity (NCE) Aug 15, 2024
New Patient Population (NPP) Oct 20, 2026

NCE-1 date: 2023-08-16

Market Authorisation Date: 15 August, 2019

Treatment: Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of ros1-positive non-small cell lung cancer; Treatment of neuroblastomas that have a neurotrop...

Dosage: CAPSULE;ORAL

More Information on Dosage

ROZLYTREK family patents

Family Patents